bluebird bio Inc. (NASDAQ:BLUE) and Intec Pharma Ltd. (NASDAQ:NTEC) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.
Table 1 shows the gross revenue, earnings per share (EPS) and valuation for bluebird bio Inc. and Intec Pharma Ltd.
Table 2 hightlights the return on assets, net margins and return on equity of the two companies.
The Recommendations and Ratings for bluebird bio Inc. and Intec Pharma Ltd. are featured in the next table.
bluebird bio Inc.’s consensus price target is $154.78, while its potential upside is 0.95%.
Insider and Institutional Ownership
Institutional investors owned 0% of bluebird bio Inc. shares and 39.64% of Intec Pharma Ltd. shares. 0.7% are bluebird bio Inc.’s share owned by insiders. Competitively, insiders own roughly 11.81% of Intec